University Hospitals

University Hospitals developed a new vision, a new strategy and a new model for healthcare delivery. This new vision called for University Hospitals to better meet the healthcare needs of a significant portion of northeast Ohio through geographic expansion and an increase in the types of services they offer.

Eric Beck

President and COO

5 past transactions

Axuall

Series B in 2023
Axuall, Inc. is a workforce intelligence company that operates a digital network designed to verify identities, credentials, and authenticity across various sectors, including healthcare, insurance, and logistics. Founded in 2018 and based in Cleveland, Ohio, Axuall offers an integrated platform that facilitates smarter decision-making and expedites the onboarding process for healthcare providers. By leveraging real-time practitioner data, the company enhances workforce deployment and efficiency, and provides critical insights for network planning, analytics, and reporting. Its solutions aim to empower healthcare professionals by granting them control over their career identities while connecting health systems, staffing firms, and telehealth organizations to valuable data resources.

STAQ Pharma

Series C in 2022
STAQ Pharma, Inc. is a Denver-based company that specializes in manufacturing and selling compounded pharmaceutical medications. Founded in 2018, it operates a current Good Manufacturing Practice (cGMP) outsourcing facility that produces a range of compounded medications, including sterile solutions and prefilled syringes for hospital procedures. The company emphasizes safety, quality, and transparency in its offerings, providing healthcare facilities with reliable access to these critical products. STAQ Pharma sells its medications through its own pharmaceutical facilities and an online store, ensuring that inventory systems are in place to forecast needs and proactively supply partners with essential medications.

Babyscripts

Series B in 2021
Babyscripts is a developer of a virtual maternity care platform aimed at enhancing prenatal and postpartum care for pregnant mothers. The company's three-tiered approach allows healthcare providers to deliver tailored, risk-specific care anytime and anywhere. The first tier features a mobile app that offers daily educational content and resources throughout pregnancy and the postpartum period. The second tier incorporates remote monitoring through medical devices, enabling patients to track health metrics like blood pressure and alerting providers to potential risks. This system facilitates the transition of care beyond traditional clinical settings, enabling providers to focus on higher-risk patients while automating routine care. The third tier fosters collaboration between care teams and insurers, addressing challenges in care coordination and access, ultimately improving health outcomes and reducing costs. Through its innovative platform, Babyscripts aims to eliminate maternal mortality and enhance access to quality care for all mothers.

BioMotiv

Venture Round in 2013
BioMotiv is a therapeutic accelerator developing a portfolio of novel medicines. BioMotiv is the mission-aligned development company of The Harrington Project for Discovery and Development. The Harrington Project, unveiled in February by University Hospitals (UH), is a first-of-its-kind $250 million initiative that promises to revolutionize how new breakthrough drugs are advanced to market. By aligning the upstream efforts of the recently created UH Case Medical Center’s Harrington Discovery Institute with the downstream development efforts of BioMotiv, The Harrington Project seeks to accelerate the therapeutic innovation process for the benefit of patients globally. The company was founded in 2012 and is headquartered in Cleveland, Ohio.

BioMotiv

Venture Round in 2012
BioMotiv is a therapeutic accelerator developing a portfolio of novel medicines. BioMotiv is the mission-aligned development company of The Harrington Project for Discovery and Development. The Harrington Project, unveiled in February by University Hospitals (UH), is a first-of-its-kind $250 million initiative that promises to revolutionize how new breakthrough drugs are advanced to market. By aligning the upstream efforts of the recently created UH Case Medical Center’s Harrington Discovery Institute with the downstream development efforts of BioMotiv, The Harrington Project seeks to accelerate the therapeutic innovation process for the benefit of patients globally. The company was founded in 2012 and is headquartered in Cleveland, Ohio.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.